Myriad Genetics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Myriad Genetics, Inc. (MYGN)
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. for potential securities fraud. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test starting January 2025.
November 18, 2024 | 3:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Myriad Genetics is under investigation for potential securities fraud after UnitedHealth announced it will stop covering GeneSight, a key product, starting January 2025.
The investigation into potential securities fraud and the loss of coverage for GeneSight by UnitedHealth are significant negative developments for Myriad Genetics. The investigation could lead to legal challenges and financial penalties, while the loss of coverage for GeneSight could impact revenue. These factors are likely to negatively affect MYGN's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100